Ligand Pharmaceuticals price to sales ratio LGND

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 20.8×
10-year median: 9.4×
Against its 10-year history: 98th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.1× to 23.3×
Peer median: 7.8×

Ligand Pharmaceuticals' price to sales ratio is 20.8× as of Oct 23, 2026.

That is above its ten-year median of 9.4×, higher than on 98% of days in the last ten years.

Over that time it ranged from 3.1× in Jun 2022 to 23.3× in Jul 2026.

The median for 10 large drugmakers of a similar size is 7.8×.

Price to sales ratio over time

median 9.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.8×	14.4×	23.3×
2025	15.3×	10.8×	21.2×
2024	13.5×	8.0×	16.6×
2023	8.1×	4.7×	8.1×
2022	4.7×	3.1×	5.7×
2021	5.9×	4.3×	14.2×
2020	7.0×	5.7×	11.2×
2019	7.7×	4.9×	8.1×
2018	7.4×	7.2×	18.3×
2017	14.0×	12.4×	16.4×
2016	14.4×	13.5×	23.5×
2015	18.3×	10.4×	21.0×
2014	13.3×	10.6×	20.5×
2013	14.4×	7.9×	17.6×
2012	8.3×	4.5×	8.7×

Against its peers

Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
AMRXAmneal Pharmaceuticals	2.1×
ALKSAlkermes plc.	4.4×
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
INDVIndivior Pharmaceuticals	3.1×
CORTCorcept Therapeutics	11.2×
ARQTArcutis Biotherapeutics	8.5×
LQDALiquidia	8.5×
OGNOrganon	0.6×
Peer median	7.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Ligand Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.